Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet? Kristen D. WhitakerDeepa ShethOlufunmilayo I. Olopade Review 03 July 2020 Pages: 243 - 250
Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound Aubriana M. McEvoySteven PoplackWilliam E. Gillanders Review 10 July 2020 Pages: 251 - 262
Spatial location of local recurrences after mastectomy: a systematic review Orit Kaidar-PersonPhilip PoortmansLiesbeth J. Boersma Review 13 July 2020 Pages: 263 - 273
TRAF4, a new substrate of SIAH1, participates in chemotherapy resistance of breast cancer cell by counteracting SIAH1-mediated downregulation of β-catenin Huayan RenXiaoyi MiHuixiang Li Review 15 July 2020 Pages: 275 - 289
Patient preferences for locoregional therapy in early-stage breast cancer Christina A. MinamiTari A. KingElizabeth A. Mittendorf Review 20 July 2020 Pages: 291 - 309
Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer Albina StockerAndreas TrojanZsuzsanna Varga Preclinical study 07 July 2020 Pages: 311 - 319
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy Kai LiNing LiaoNing Liao Preclinical study Open access 07 July 2020 Pages: 321 - 332
CDH2/N-cadherin and early diagnosis of invasion in patients with ductal carcinoma in situ Marina A. GuvakovaIndira PrabakaranPaul J. Zhang Preclinical study 18 July 2020 Pages: 333 - 346
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer C. CriscitielloA. VingianiG. Curigliano Clinical trial 03 July 2020 Pages: 347 - 354
Clinical decision trees support systematic evaluation of multidisciplinary team recommendations Mathijs P. HendriksXander A. A. M. VerbeekAgnes Jager Clinical trial Open access 06 July 2020 Pages: 355 - 363
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients Adrienne E. BorrieFinnley A. RoseRichard B. Kim Clinical trial 06 July 2020 Pages: 365 - 372
External validation and modification of nomogram for predicting positive resection margins before breast conserving surgery Ji-Jung JungEunyoung KangHee-Chul Shin Clinical trial 09 July 2020 Pages: 373 - 380
Assessing preferences for receiving supportive care resources among patients seen at a Breast Care Center Emily C. WongCelia P. KaplanMichelle Melisko Clinical trial 09 July 2020 Pages: 381 - 389
Patient-reported acute fatigue in elderly breast cancer patients treated with and without regional nodal radiation Shagun MisraGrace LeeJoelle Helou Clinical trial 10 July 2020 Pages: 391 - 401
The shape of breast cancer Brook K. ByrdVenkataramanan KrishnaswamyRichard J. Barth Jr Clinical trial 12 July 2020 Pages: 403 - 410
Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer Bahar MoftakharManidhar LekkalaAjay Dhakal Clinical trial 15 July 2020 Pages: 411 - 418
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) Richard S. FinnKatalin BoerJohannes Ettl Clinical trial Open access 18 July 2020 Pages: 419 - 428
Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database Zhong-Li DuYang WangBai-Lin Zhang Epidemiology 17 July 2020 Pages: 429 - 438
Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study Milena SantElisabetta Meneghinithe European High Resolution Working Group on breast cancer Epidemiology 10 July 2020 Pages: 439 - 450
“Are changes in breast density during the menstrual cycle relevant? To what?” Jean L. BrowneNatalie KorsunM. Angela Pascual Epidemiology 15 July 2020 Pages: 451 - 458
Racial differences in the relationship between surgical choice and subsequent patient-reported satisfaction outcomes among women with early-stage hormone-positive breast cancer Prudvi ArabandiAlexander N. SladeVanessa Sheppard Epidemiology 16 July 2020 Pages: 459 - 466
Obesity and related conditions and risk of inflammatory breast cancer: a nested case–control study Catherine SchairerCecile A. LaurentLawrence H. Kushi Epidemiology 20 July 2020 Pages: 467 - 478
Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials Kyaw Zin TheinThura Win HtutThein Hlaing Oo Brief Report 09 July 2020 Pages: 479 - 487
Variation in pathological complete response in HER2-positive breast cancers with intrinsic subtypes assessed by PAM50 testing: secondary analysis from NSABP B-41 trial Arun Kumar GoelVaishali ZamreShreebha Hari Letter to the Editor 09 July 2020 Pages: 489 - 490
Correction to: Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis Blanche P. AlterAna F. Best Correction 08 July 2020 Pages: 491 - 491
Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer Ahrong HamMin Hwan KimJoohyuk Sohn Correction 14 July 2020 Pages: 493 - 493